Inactive Instrument
Norda ASA Stock Oslo Bors
Stocks
NORD
NO0010285190
Biotechnology & Medical Research
| Market Cap | 513M 52.57M 45.99M 42.42M 39.17M 74.33M 5.01B 75.58M 507M 199M 2.47B 197M 193M 8.49B | P/E 2023 * |
-
| P/E 2024 | 3.26x |
|---|---|---|---|---|---|
| Enterprise Value | 264M 27.08M 23.69M 21.85M 20.18M 38.29M 2.58B 38.94M 261M 103M 1.27B 102M 99.47M 4.37B | EV / Sales 2023 |
-1.24x | EV / Sales 2024 | 0.4x |
| Free-Float |
6.26% | Yield 2023 * |
-
| Yield 2024 | 32.5% |
| 04-09 | Exercise of Warrants by primary insiders | AQ |
| 10/07/25 | Mandatory Notification of Trade | AQ |
| 04/06/25 | Ocean Sun: Mandatory notification of trade | AQ |
| 27/03/25 | Nykode Therapeutics - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | AQ |
| 03/03/25 | Notification of trade | AQ |
| 1 day | +3.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
Frode Westvold
CEO | Chief Executive Officer | - | 08/04/2013 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 31/01/2014 | |
| Director/Board Member | 68 | 20/06/2013 | |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.37% | -6.12% | - | - | 45.42M | ||
| +0.58% | +2.06% | +2.92% | +10.86% | 50.73B | ||
| -2.22% | -1.25% | +385.40% | +586.81% | 39.73B | ||
| -0.54% | +0.39% | +25.57% | -5.28% | 34.69B | ||
| -1.36% | +0.35% | +17.88% | +55.14% | 33.21B | ||
| +1.21% | -4.58% | +3.00% | +35.46% | 26.76B | ||
| -1.81% | -1.48% | - | - | 16.8B | ||
| +0.51% | -3.47% | +63.97% | +122.60% | 15.37B | ||
| +0.23% | -0.58% | +13.76% | +21.11% | 13.78B | ||
| -0.62% | -3.09% | +10.29% | -31.35% | 12.85B | ||
| Average | -0.07% | -0.83% | +65.35% | +99.42% | 27.1B | |
| Weighted average by Cap. | -0.48% | -0.23% | +80.69% | +124.32% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 86.92M 8.9M 7.79M 7.18M 6.64M 12.59M 849M 12.8M 85.84M 33.71M 418M 33.43M 32.71M 1.44B | 372M 38.1M 33.32M 30.74M 28.39M 53.86M 3.63B 54.77M 367M 144M 1.79B 143M 140M 6.15B |
| Net income | 31.17M 3.19M 2.79M 2.58M 2.38M 4.52M 305M 4.59M 30.79M 12.09M 150M 11.99M 11.73M 516M | 126M 12.9M 11.29M 10.41M 9.61M 18.24M 1.23B 18.55M 124M 48.84M 606M 48.45M 47.39M 2.08B |
| Net Debt | -311M -31.89M -27.89M -25.73M -23.76M -45.08M -3.04B -45.84M -307M -121M -1.5B -120M -117M -5.15B | -249M -25.49M -22.3M -20.57M -18.99M -36.04M -2.43B -36.65M -246M -96.5M -1.2B -95.71M -93.63M -4.12B |
Employees
-
















